Canadian Drug Trial Aims to Protect Brains of Dialysis Patients

TORONTO, ON – March 24, 2026 – A groundbreaking clinical trial has begun in Canada, offering a new ray of hope for millions of patients who rely on hemodialysis. Vasomune Therapeutics, in collaboration with Japan-based AnGes, Inc., announced that the first patient has been dosed with Pegevongitide (AV-001), a novel, made-in-Canada drug candidate designed to prevent the devastating brain injuries that can accompany life-saving dialysis treatments.

The study marks a pivotal moment in nephrology, shifting focus from solely managing kidney failure to proactively protecting the brain, one of the organs most vulnerable to the rigors of hemodialysis. Led by a top Canadian researcher, the trial will investigate if Pegevongitide can stabilize the brain's delicate blood vessels during the circulatory stress of dialysis, potentially shielding patients from cognitive decline.

The Silent Burden of Dialysis

For patients with end-stage kidney disease, hemodialysis is a lifeline, performing the vital blood-filtering function their own organs no longer can. However, this life-sustaining therapy carries a significant and often under-recognized risk: a silent assault on the brain. The procedure, which involves rapid shifts in fluid and blood pressure, places immense stress on the entire vascular system. The brain is particularly susceptible to this 'circulatory stress.'

Research has shown that this repeated stress can lead to cerebrovascular destabilization and recurrent ischemic brain injury—essentially, small, often unnoticed strokes. The cumulative effect is severe. Studies indicate that a staggering 70% of patients initiating routine hemodialysis experience some form of vascular cognitive impairment. This can range from mild 'brain fog' and memory lapses to moderate or severe dementia, profoundly impacting a patient's quality of life, independence, and ability to adhere to complex medical regimens.

Until now, the standard of care has lacked a specific pharmacological defense. While some non-pharmacological strategies, such as cognitive training during sessions or modifying dialysis parameters like cooling the dialysate, are being explored, they have shown limited or inconsistent benefits. There is no approved drug specifically designed to prevent this acute, treatment-induced brain injury, leaving a critical unmet need in this large and vulnerable patient population.

A Canadian-Led Scientific Breakthrough

Pegevongitide represents a novel pharmacological approach to this problem. The drug is a Tie2 receptor agonist, designed to activate the Tie2/Angiopoietin-1 signaling pathway. In simple terms, this pathway is a master regulator of vascular health. Activating it helps to strengthen the junctions between endothelial cells, effectively fortifying blood vessel walls, preventing leakage, and reducing inflammation.

By administering Pegevongitide before a dialysis session, researchers hope to 'pre-condition' the cerebral vasculature, making it more resilient to the intense hemodynamic fluctuations that follow. The goal is to keep the brain's blood vessels stable and intact, thereby preventing the ischemic damage that fuels cognitive decline.

The trial's credibility is bolstered by its leadership. The study is spearheaded by Dr. Christopher McIntyre, a world-renowned nephrologist and Professor at Western University, where he holds the Robert Lindsay Chair of Dialysis Research and Innovation. As Director of the Lilibeth Caberto Kidney Clinical Research Unit, Dr. McIntyre's recent work has focused intensely on mitigating the unintended, multi-organ consequences of dialysis itself. His expertise lends significant weight to the trial's design and potential impact.

"Hemodialysis patients are uniquely vulnerable to recurrent ischemic brain injury caused by circulatory stress during treatment," Dr. McIntyre noted in the initial announcement, underscoring the urgency of the research. "Pegevongitide (AV-001) offers a promising new approach to maintain their overall brain health."

A Strategic Alliance for Vascular Health

The development of Pegevongitide is a story of strategic collaboration and focused science. Vasomune Therapeutics, a private Toronto-based biotech founded in 2014, has built its entire platform around developing medicines that combat vascular leak. This trial represents a significant expansion for the company, moving its core technology from applications in acute respiratory distress syndrome (ARDS) and sepsis into the chronic care setting of nephrology.

This expansion is supported by a robust partnership with AnGes, Inc., a publicly traded Japanese biopharmaceutical company specializing in gene-based medicines. Their co-development agreement, initially focused on pneumonia, was recently expanded to include this new indication in hemodialysis patients, with AnGes providing millions in milestone-based financial support to Vasomune. This demonstrates strong confidence in the drug's mechanism and its potential across different diseases characterized by vascular instability.

Furthermore, Vasomune has successfully leveraged non-dilutive funding to accelerate its research, securing over $13 million in grants from prestigious bodies like the U.S. Department of Defense and the National Research Council of Canada. This external validation has been crucial in advancing Pegevongitide from a laboratory concept to a clinical-stage asset without relying solely on venture capital.

The Path Forward: Protecting Patients and Pipelines

The initiation of this trial is a critical first step. If the study demonstrates that Pegevongitide is safe and effective in preventing acute brain injury, it will pave the way for a larger, confirmatory trial. Success would be transformative, not just for the companies involved, but for the entire field of dialysis care.

For patients, it could mean the arrival of the first-ever drug to protect their cognitive function, preserving their personhood and quality of life while they undergo essential treatment. It would represent a paradigm shift toward a more holistic approach to dialysis, acknowledging that patient well-being extends far beyond balancing electrolytes and removing toxins.

For Vasomune and AnGes, a positive outcome would validate their scientific platform and open a substantial new market. It would position Pegevongitide as a first-in-class therapy addressing a complication that affects millions of dialysis patients worldwide. As the trial progresses, the medical community and patients alike will be watching closely, hopeful that this innovative Canadian drug can finally address one of the most serious hidden costs of surviving kidney failure.